Evicenter
MarkdownMedical informationP&T meetings
Lonvoguran ziclumeran (lonvo-z)

Hereditary angioedema

Also known as NTLA-2002
Last updated
82 sources

Section 6 of 6

References

82 sources

  1. Arora et al. (2023) (opens in a new tab)
  2. Banerji et al. (2018) (opens in a new tab)
  3. Banerji et al. (2026) (opens in a new tab)
  4. Beard et al. (2022) (opens in a new tab)
  5. Betschel et al. (2026) (opens in a new tab)
  6. Broderick et al. (2025) (opens in a new tab)
  7. Busse et al. (2021) (opens in a new tab)
  8. Busse et al. (2026) (opens in a new tab)
  9. Castaldo et al. (2021) (opens in a new tab)
  10. Cohn et al. (2025) (opens in a new tab)
  11. Cohn et al. (2026) (opens in a new tab)
  12. Craig et al. (2023) (opens in a new tab)
  13. Craig et al. (2026) (opens in a new tab)
  14. CSL (2023) (opens in a new tab)
  15. CSL Behring (2022) (opens in a new tab)
  16. CSL Behring (2026) (opens in a new tab)
  17. EU Clinical Trials Register 2013-000916-10 (opens in a new tab)
  18. Farkas and Balla (2024) (opens in a new tab)
  19. FDA (2018) (opens in a new tab)
  20. FDA (2020) (opens in a new tab)
  21. FDA ANDEMBRY prescribing information (2025) (opens in a new tab)
  22. FDA DAWNZERA prescribing information (2025) (opens in a new tab)
  23. FDA Drug Trials Snapshots ANDEMBRY (2025) (opens in a new tab)
  24. FDA Drug Trials Snapshots DAWNZERA (2025) (opens in a new tab)
  25. FDA Drug Trials Snapshots EKTERLY (2025) (opens in a new tab)
  26. Feld et al. (2026) (opens in a new tab)
  27. Guan et al. (2024) (opens in a new tab)
  28. Henao et al. (2016) (opens in a new tab)
  29. ICER (2021) (opens in a new tab)
  30. Intellia Therapeutics (2022) (opens in a new tab)
  31. Intellia Therapeutics (2023) (opens in a new tab)
  32. Intellia Therapeutics (2024) (opens in a new tab)
  33. Intellia Therapeutics (2025) (opens in a new tab)
  34. Intellia Therapeutics AAAAI poster (2025) (opens in a new tab)
  35. Intellia Therapeutics AAAAI presentation (2021) (opens in a new tab)
  36. Intellia Therapeutics ACAAI poster (2025) (opens in a new tab)
  37. Intellia Therapeutics ACAAI presentation (2025) (opens in a new tab)
  38. Intellia Therapeutics additional HAELO phase 3 results announcement (2026) (opens in a new tab)
  39. Intellia Therapeutics BLA acceptance announcement (2026) (opens in a new tab)
  40. Intellia Therapeutics corporate overview (2026) (opens in a new tab)
  41. Intellia Therapeutics EAACI presentation (2025) (opens in a new tab)
  42. Intellia Therapeutics EAACI presentation (2026) (opens in a new tab)
  43. Intellia Therapeutics Form 10-K (2026) (opens in a new tab)
  44. Intellia Therapeutics Form 10-Q (2026) (opens in a new tab)
  45. Intellia Therapeutics HAELO first patient dosed announcement (2025) (opens in a new tab)
  46. Intellia Therapeutics HAELO phase 3 results announcement (2026) (opens in a new tab)
  47. Intellia Therapeutics HAELO topline data presentation (2026) (opens in a new tab)
  48. Intellia Therapeutics investor presentation (2024) (opens in a new tab)
  49. Intellia Therapeutics presentation (2026) (opens in a new tab)
  50. Intellia Therapeutics rolling BLA submission announcement (2026) (opens in a new tab)
  51. Intellia Therapeutics third quarter 2026 results (2026) (opens in a new tab)
  52. Ionis Pharmaceuticals protocol and statistical analysis plan (2023) (opens in a new tab)
  53. Jalal et al. (2025) (opens in a new tab)
  54. Kaplan et al. (2026) (opens in a new tab)
  55. Kutrieb et al. (2026) (opens in a new tab)
  56. Longhurst et al. (2017) (opens in a new tab)
  57. Longhurst et al. (2023) (opens in a new tab)
  58. Longhurst et al. (2024) (opens in a new tab)
  59. Lumry et al. (2021) (opens in a new tab)
  60. Luong et al. (2026) (opens in a new tab)
  61. Magerl et al. (2026) (opens in a new tab)
  62. Maurer et al. (2022) (opens in a new tab)
  63. MedlinePlus (opens in a new tab)
  64. Olson et al. (2026) (opens in a new tab)
  65. Pardi and Ivics (2024) (opens in a new tab)
  66. Princic et al. (2025) (opens in a new tab)
  67. Riedl et al. (2024a) (opens in a new tab)
  68. Riedl et al. (2024b) (opens in a new tab)
  69. Sandberg et al. (2024) (opens in a new tab)
  70. Somatic Cell Gene Editing Consortium NCT05120830 (opens in a new tab)
  71. Somatic Cell Gene Editing Consortium NCT06634420 (opens in a new tab)
  72. Uminski et al. (2025) (opens in a new tab)
  73. US Hereditary Angioedema Association (opens in a new tab)
  74. Vanya et al. (2023) (opens in a new tab)
  75. Vázquez et al. (2026) (opens in a new tab)
  76. Villa et al. (2026) (opens in a new tab)
  77. Walsh et al. (2022) (opens in a new tab)
  78. Walsh et al. (2025) (opens in a new tab)
  79. Watt et al. (2026) (opens in a new tab)
  80. Weller et al. (2016) (opens in a new tab)
  81. Zuraw et al. (2021) (opens in a new tab)
  82. Zuraw et al. (2025) (opens in a new tab)